Novavax files submission to UK regulator for Covid-19 vaccine approval after Blackpool trial

Home | Blackpool Gazette

The final data on the Novavax coronavirus vaccine has been submitted to the UK regulator for approval.


The firm behind the vaccine said it anticipates a “positive decision” following the completion of its rolling regulatory submission to the Medicines and Healthcare products Regulatory Agency (MHRA).

More than 15,000 people took part in the phase 3 Novavax trial at various hospital sites across the UK, including Blackpool.

Novavax said its application for conditional marketing authorisation (CMA) marks the first submission for authorisation of a protein-based coronavirus vaccine in the UK.

File image by Jonathan Gawthorpe

File image by Jonathan Gawthorpe

Britain has ordered 60 million doses of the vaccine.

Novavax boss Stanley Erck thanked all trial participants.